CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 196 enrolled
Drug / intervention
ESA +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02238067
NCT02238067N/ACompleted

Survey on Anemia Therapy With ESAs Medication in Chronic Kidney Disease Patients Not on Dialysis

Hoffmann-La Roche·observational·Posted Sep 12, 2014·Updated Mar 24, 2017

In Brief

An observational study evaluating ESA and Satisfaction Survey Questionnaire for Chronic Kidney Diseases. Completed, enrolled 196 participants across 7 sites.

Detailed Summary

This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis participant population in Israel. Participating physicians will be requested to interview eligible participants with CKD not on dialysis and to complete for them a satisfaction survey for anemia treatment. The survey will be completed twice, once at study start and once at six months' follow-up.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2014
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.8 years ago

Interventions

ESAdrug

Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.

Satisfaction Survey Questionnaireother

Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.